07:44 AM EDT, 08/19/2024 (MT Newswires) -- Redhill Biopharma ( RDHL ) said Monday that it achieved positive results from multiple in vivo studies conducted by RedHill's partner, Apogee Biotechnology Corporation, supporting the potential clinical use of opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.

Opaganib treatment reduced weight gain and restored glucose tolerance in an already obese high-fat diet model, the company said.

The company's share price jumped almost 23% in recent premarket activity on Monday.

Price: 0.3460, Change: +0.06, Percent Change: +19.27